Detection frequency and duration of lupus anticoagulant circulation in COVID-19 patients
- Authors: Beznoshchenko O.S.1, Shpilyuk M.A.1, Ivanets T.Y.1, Krechetova L.V.1, Pyregov A.V.1, Kodatsky D.S.1, Tavluyeva E.V.2, Melkumyan A.R.2, Gorodnova E.A.1, Dolgushina N.V.1
-
Affiliations:
- V. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
- F. Inozemtsev City Clinical Hospital
- Issue: Vol 24, No 3 (2021)
- Pages: 413-418
- Section: SHORT COMMUNICATIONS
- Submitted: 08.07.2021
- Accepted: 20.08.2021
- Published: 15.07.2021
- URL: https://rusimmun.ru/jour/article/view/1042
- DOI: https://doi.org/10.46235/1028-7221-1042-DFA
- ID: 1042
Cite item
Full Text
Abstract
The aim of the work was to determine frequency of lupus anticoagulant (LA) detection in patients at various degrees of COVID-19 severity as well as duration of LA circulation after the infectious disease. The study included 103 patients with COVID-19. The patients were observed during the hospital care and in ambulance, if required. The patients were admitted to the departments of infectious diseases arranged at the V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology, and F.I. Inozemtsev City Clinical Hospital. Treatment schedules and stratification of the patients by clinical severity was carried out in accordance with Interim Guidelines issued by the Ministry of Health of the Russian Federation for the prevention, diagnosis and treatment of new coronavirus infection (version 9). The following groups were formed: mild (n = 27), moderate (n = 55) and severe (n = 20). The patients were tested for LA positivity in the course of disease: on the day of starting medical care (with outpatient observation), or on the day of hospitalization; repeated tests were made before discharge (inpatients), and later, 1-2 months and 7 months after recovery. Lupus anticoagulant was determined by two independent tests (dRVVT and SCT), i.e., as a screening test and a confirmation test. At initial examination, LA was found in 50 patients (49%). The effect of LA in 98% of cases was observed with dRVVT test, as an increase of normalized ratio (NR). The maximum median value of NR was 1.54 (0.97: 2.1) was revealed in patients with severe course of COVID-19 (p < 0.0001) compared with other groups and correlated with severity of the infectious process (r = 0.491, p < 0.0001). In mild cases of COVID-19, LA was detected less often (4 cases, 14.8%) than in moderate severity cases (27, 49.1%), and severe patients (19, 95%) (p < 0.05). Re-examinations of the patients before discharge from the hospital and 1-2 months later revealed high frequency of LA (p < 0.05). However, no LA-positive test was found 7 months after discharge. In patients with COVID-19, high frequency of circulating LA was registered, depending on severity of the infectious process. In addition, we have first shown that persistence of the circulating LA over post-infectious period does not exceed 7 months.
Keywords
About the authors
O. S. Beznoshchenko
V. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Author for correspondence.
Email: ospa-a@yandex.ru
ORCID iD: 0000-0003-4645-8976
Doctor for Clinical Laboratory Diagnostics, Junior Research Associate, Laboratory of Clinical Immunology
117997, Moscow, Acad. Oparin str., 4
Russian FederationM. A. Shpilyuk
V. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Email: tambovtsevamr@mail.ru
ORCID iD: 0000-0001-5145-7981
Research Associate, Laboratory of Clinical Immunology
117997, Moscow, Acad. Oparin str., 4
Russian FederationT. Yu. Ivanets
V. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Email: t_ivanets@oparina4.ru
ORCID iD: 0000-0002-7990-0276
PhD, MD (Medicine), Head, Clinical Diagnostic Laboratory
117997, Moscow, Acad. Oparin str., 4
Russian FederationL. V. Krechetova
V. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Email: l_krechetova@oparina4.ru
ORCID iD: 0000-0001-5023-3476
PhD, MD (Medicine), Head, Laboratory of Clinical Immunology
117997, Moscow, Acad. Oparin str., 4
Russian FederationA. V. Pyregov
V. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Email: a_pyregov@oparina4.ru
ORCID iD: 0000-0001-8382-9671
PhD, MD (Medicine), Professor, Director of the Institute of Anesthesiology, Reanimatology and Transfusiology
117997, Moscow, Acad. Oparin str., 4
Russian FederationD. S. Kodatsky
V. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Email: d_kodatskiy@oparina4.ru
ORCID iD: 0000-0001-9707-3473
Anesthesiologist-Reanimatologist
117997, Moscow, Acad. Oparin str., 4
Russian FederationE. V. Tavluyeva
F. Inozemtsev City Clinical Hospital
Email: tavlev@mail.ru
PhD, MD (Medicine), Deputy Chief Physician for Medical Affairs
Moscow
Russian FederationA. R. Melkumyan
F. Inozemtsev City Clinical Hospital
Email: alinamelkumyan@yandex.ru
PhD (Medicine), Doctor for Clinical Laboratory Diagnostics, Head, Center of the Laboratory Diagnostics
Moscow
Russian FederationE. A. Gorodnova
V. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Email: e_gorodnova@oparina4.ru
ORCID iD: 0000-0002-9524-4416
PhD (Medicine), Head, Center for Scientific and Clinical Research
117997, Moscow, Acad. Oparin str., 4
N. V. Dolgushina
V. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Email: n_dolgushina@oparina4.ru
PhD, MD (Medicine), Professor, Deputy Director, Head, Department of Organization of Scientific Activities
117997, Moscow, Acad. Oparin str., 4
Russian FederationReferences
- Devreese K.M.J., Linskens E.A., Benoit D., Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: a relevant observation? J. Thromb. Haemost., 2020, Vol. 18, no. 9, pp. 2191-2201.
- Harzallah I., Debliquis A., Drénou B. Lupus anticoagulant is frequent in patients with Covid-19. J. Thromb. Haemost., 2020, Vol. 18, no. 8, pp. 2064-2065.
- Helms J., Tacquard C., Severac F., Leonard-Lorant I., Ohana M., Delabranche X., Merdji H., Clere-Jehl R., Schenck M., Fagot Gandet F., Fafi-Kremer S., Castelain V., Schneider F., Grunebaum L., Anglés-Cano E., Sattler L., Mertes P.M., Meziani F.; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med., 2020, Vol. 46, no. 6, pp. 1089-1098.
- Sayar Z., Moll R., Isenberg D., Cohen H. Thrombotic antiphospholipid syndrome: a practical guide to diagnosis and management. Thromb. Res., 2021, no. 198, pp. 213-221.
- Spihlman A.P., Gadi N., Wu S.C., Moulton V.R. COVID-19 and Systemic Lupus Erythematosus: Focus on Immune Response and Therapeutics. Front. Immunol., 2020, Vol. 11, 589474. doi: 10.3389/fimmu.2020.589474.
- Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost., 2020, Vol. 18, no. 4, pp. 844-847.
- Wahl D.G., Guillemin F., de Maistre E., Perret-Guillaume C., Lecompte T., Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus. 1998, Vol. 7, no. 1, pp. 15-22.
- Zuo Y., Estes S.K., Ali R.A., Gandhi A.A., Yalavarthi S., Shi H., Sule G., Gockman K., Madison J.A., Zuo M., Yadav V., Wang J., Woodard W., Lezak S.P., Lugogo N.L., Smith S.A., Morrissey J.H., Kanthi Y., Knight J.S. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med., 2020, Vol. 12, no. 570, eabd3876. doi: 10.1126/scitranslmed.abd3876.